New drug aims to slash relapse rate in rare nerve disease
Disease control
Not yet recruiting
This study tests a drug called ravulizumab in about 21 Chinese adults with a rare nerve disease called NMOSD. The goal is to see if it can reduce the number of attacks (relapses) and slow disability. Participants must have had at least one attack in the past year and be on stable…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC